This article presents for the first time the potential of 830-nm spectral domain optical coherence tomography (SD-OCT) in the evaluation of Fuchs' endothelial dystrophy. SD-OCT is an imaging technique that can be used for in vivo cross-sectional corneal visualization. The important features of SD-OCT instruments include improved sensitivity and short acquisition time, which improves the quality of the tomograms compared with conventional time domain OCT. Tomograms of the corneas of three patients in different stages of Fuchs' endothelial dystrophy are presented. The authors conclude that 830-nm SD-OCT provides clinically valuable cross-sectional assessment of pathomorphological changes in Fuchs' endothelial dystrophy in vivo.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3928/15428877-20090301-11 | DOI Listing |
Purpose: To investigate the effectiveness of mitochondrial-targeted antioxidant mitoquinone (MitoQ) and nontargeted antioxidant idebenone (Idb) in alleviating mitochondrial dysfunction in corneal endothelial cells (CEnCs).
Methods: In vitro experiments were conducted using immortalized normal human corneal endothelial cells (HCEnC-21T; SVN1-67F) and Fuchs endothelial corneal dystrophy (FECD) cells (SVF5-54F; SVF3-76M). Cells were pretreated with MitoQ or Idb and then exposed to menadione (MN) with simultaneous antioxidant treatment.
Cornea
January 2025
Department of Ophthalmology and Visual Sciences, Case Western Reserve University School of Medicine, University Hospitals Eye Institute, Cleveland, OH.
Purpose: Describe aims, methods, characteristics of donors, donor corneas and recipients, and potential impact of the Diabetes Endothelial Keratoplasty Study (DEKS).
Methods: The DEKS is a randomized, clinical trial to assess graft success and endothelial cell density (ECD) 1 year after Descemet membrane endothelial keratoplasty (DMEK) using corneas from donors with versus without diabetes in a 1:2 minimization assignment. Diabetes severity in the donor is assessed by medical history, postmortem HbA1c, and donor skin advanced glycation end-products and oxidation markers.
Cornea
January 2025
School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA.
Clin Ophthalmol
January 2025
Department of Pediatrics, Faculty of Medicine, Chulalongkorn University Bangkok, Bangkok, Thailand.
Purpose: To describe the demographic profile, clinical characteristics, and treatment trends of Fuchs endothelial corneal dystrophy (FECD) in Thai patients, reflecting the evolving landscape of corneal transplantation in this region.
Patients And Methods: This retrospective cohort study included 900 patients (1,743 eyes) diagnosed with FECD at a tertiary referral center in Thailand between January 2017 and June 2023. Demographic, clinical, and surgical data were analyzed, focusing on best-corrected visual acuity (BCVA), central corneal thickness (CCT), endothelial cell density (ECD), surgical interventions, and graft survival rate.
Cornea
January 2025
Department of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe, Japan.
Purpose: Fuchs endothelial corneal dystrophy (FECD) displays a higher incidence in females than in males, yet the underlying mechanism remains unclear. This study aimed to elucidate sex-dependent differential gene expressions in corneal endothelial cells (CECs) from healthy non-FECD individuals and from patients with FECD.
Methods: RNA-Seq data from CECs of non-FECD subjects (3 males, 4 females) and FECD subjects (5 males, 5 females) were analyzed to identify differentially expressed genes (DEGs) between the sexes.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!